-+ 0.00%
-+ 0.00%
-+ 0.00%

Amylyx signs Bachem manufacturing deal for avexitide supply starting 2028

PUBT·09/08/2026 20:55:14
Listen to the news
Amylyx signs Bachem manufacturing deal for avexitide supply starting 2028
  • Signed a manufacturing and supply agreement with Bachem Americas to produce avexitide drug substance for commercial use, if approved.
  • Entered a term sheet with Polypeptide Group for a second non-exclusive supply source covering long-term avexitide needs starting in 2028.
  • Polypeptide deal includes a USD 30 million upfront capacity reservation fee, subject to a definitive manufacturing agreement.
  • Bachem contract sets annual minimum purchase commitments from 2028, with prices adjusted yearly for cost inflation.
  • Bachem agreement runs five years with automatic three-year renewals; both suppliers are non-exclusive, allowing alternate manufacturers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-385331), on September 08, 2026, and is solely responsible for the information contained therein.